OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 01:59 UTC. Every row links to its source record.

PDGFB platelet derived growth factor subunit B

ENSG00000100311 · protein coding · Open Targets profile

Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin (PubMed:26599395). Required for normal proliferation and recruitment of pericytes and vascular smooth muscle cells in the central nervous system, skin, lung, heart and placenta. Required for normal blood vessel development, and for normal development of kidney glomeruli. Plays an important role in wound healing. Signaling is modulated by the formation of heterodimers with PDGFA (By similarity). .

In 14 of 15 cancers, the evidence for PDGFB comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751meningiomameningiomameningioma: germline 0.60dermatofibrosarcoma protuberansdermatofibrosarcoma protuberansdermatofibrosarcoma protuberans: somatic 0.61dermatofibrosarcoma protuberans: germline 0.19malignant peripheral nerve sheath tumormalignant peripheral nerve sheath tumormalignant peripheral nerve sheath tumor: somatic 0.61leiomyosarcomaleiomyosarcomaleiomyosarcoma: somatic 0.61undifferentiated pleomorphic sarcomaundifferentiated pleomorphic sarcomaundifferentiated pleomorphic sarcoma: somatic 0.61cutaneous fibrous histiocytomacutaneous fibrous histiocytomacutaneous fibrous histiocytoma: somatic 0.61congenital fibrosarcomacongenital fibrosarcomacongenital fibrosarcoma: somatic 0.61nodular fasciitisnodular fasciitisnodular fasciitis: somatic 0.61monophasic synovial sarcomamonophasic synovial sarcomamonophasic synovial sarcoma: somatic 0.61gastric carcinomagastric carcinomagastric carcinoma: somatic 0.46lung carcinomalung carcinomalung carcinoma: somatic 0.46hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46breast carcinomabreast carcinomabreast carcinoma: somatic 0.46pancreatic ductal adenocarcinomapancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma: somatic 0.46non-small cell lung carcinomanon-small cell lung carcinomanon-small cell lung carcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Antibody
GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
Other modalities
Advanced Clinical

gnomAD loss of function constraint: o/e 0.20681999623775482 (upper bound 0.40821000933647156). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of PDGFB's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of PDGFB's drugs are registered

All 1 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
PEGPLERANIB SODIUMUnknownwithdrawalwet macular degeneration, age-related macular degeneration, macular degeneration, proliferative diabetic retinopathy, choroidal neovascularization, diabetes mellitus, cystoid macular edema, Retinal capillary hemangioma, +4 moreOpen Targets · ChEMBL